Who we are
Oblita Therapeutics is a global health research & development company dedicated to the development of new affordable medicines for the treatment of infectious diseases causing public health treats in the world.
Caroline Jansen is the founder of the company in 2016. Her father, MD spec in Internal Medicine (University of Leuven), PhD Biochemistry (University of London) dedicated his life for 40 years to drug development, of which he focused the last 20 years on infectious diseases. As he passed away too soon and too suddenly she wants to finish the open ends of the ongoing research projects.
Having worked as an advisor for the Belgian government on policies affecting the developing world, her heart goes out to the “forgotten” patient groups in these areas who deserve that their unmet medical needs are met. The projects are too promising for not being further developed.
Our focus
Leishmaniasis and Invasive Fungal Infections
Oblita Therapeutics’s lead program is focused on the development of a new drug (D121) to treat leishmaniasis, the 9th largest infectious disease burden for humans in the world.
Twelve million people are infected with Leishmania worldwide and an estimated 350 million people are at risk for infection. There are about 2 million new cases and 50,000 deaths each year from leishmaniasis.
With a global prevalence of Canine Leishmaniasis estimated at 15.2%, around 135 million dogs are at risk. Untreated Canine Leishmaniasis often leads to severe health complications and can be fatal.
Oblita’s R&D is also working on a new treatment for some invasive fungal infections (IFIs). Severe fungal infections form a significant global health concern, with increasing incidence rates (6.5 mio people) and annual mortality rates (3.8 mio deaths).
Our motivation
We have a global focus on a One Health approach. That means emphasizing the interconnectedness of human, animal, and environmental health in addressing infectious diseases. This is very relevant for many infectious diseases as they affect multiple species and can spread across ecosystems, posing significant public health and economic risks.
Therefor Oblita works in parallel on the development of new treatments for human and animal infectious diseases as over 60% of emerging infectious diseases are zoonotic.
How we work
Our goal is to work in the most lean and cost-efficient way by outsourcing or working in partnerships.
Oblita Therapeutics will apply pharmaceutical industry drug development approaches in the setting of severe infectious diseases. Our strength is to provide project leadership and management, pharmaceutical development & production management, clinical research management and regulatory management, sourcing the balance of the project team skills from the best (external) expert service providers, no matter where they are located, to match the project.
Closely monitoring the development costs by bringing them down to the lowest level possible but always complying to the highest European GLP, GMP , GCP … standard procedures is the only way forward to result in new high quality, safe, effective and affordable drugs for many severe infectious diseases threatening public health.